Xidian Pharmaceutical (301130) shareholder Hengqin Dingdian and its concerted actors plan to reduce their holdings by no more than 2.26M shares, accounting for 3% of the total share capital.

Log in to Sina Finance APP and search for [Information Disclosure] to see more evaluation levels

On March 25, 2026, Jilin Xidian Pharmaceutical Technology Development Co., Ltd. (hereinafter referred to as “Xidian Pharmaceutical,” stock code: 301130) announced that the company’s shareholders holding more than 5%, Hengqin Dingtian Equity Investment Fund Partnership (Limited Partnership) (hereinafter referred to as “Hengqin Dingtian”) and its concerted action partner Zhuhai Hengqin Runhuiyi Investment Partnership (Limited Partnership) (hereinafter referred to as “Hengqin Runhuiyi”) plan to reduce their holdings of the company’s shares, with a total reduction of no more than 2.26M shares, accounting for 3% of the company’s total share capital (excluding repurchased shares).

Details of Shareholder Holdings and Reduction Plan

The announcement shows that as of the disclosure date of this announcement, Hengqin Dingtian and its concerted action partner Hengqin Runhuiyi jointly hold 7.2M shares of Xidian Pharmaceutical, accounting for 9.5313% of the company’s total share capital (excluding repurchased shares) of 75.49M shares. All these shares were held before the company’s initial public offering.

In this reduction plan, Hengqin Dingtian and Hengqin Runhuiyi intend to reduce their holdings through two methods: centralized bidding transactions and block trades. Specifically:

• Centralized bidding transactions: From the date of this announcement for a period of three months (i.e., from April 17, 2026, to July 16, 2026), the total reduction will not exceed 755,000 shares, representing 1% of the company’s total share capital (excluding repurchased shares);
• Block trades: During the same period, the total reduction will not exceed 1.51M shares, accounting for 2% of the company’s total share capital (excluding repurchased shares).

If there are changes in share capital due to stock dividends, capital reserve transfers, or other capital adjustments during this period, the reduction amount will be adjusted accordingly.

Reasons for Reduction and Source of Shares

The announcement states that the reason for this reduction is due to the capital needs of Hengqin Dingtian and Hengqin Runhuiyi themselves. The shares to be reduced come from shares held before the company’s initial public offering. The price for reduction will be determined based on the secondary market price and trading method at the time of reduction.

Shareholder Commitment Performance

Hengqin Dingtian and Hengqin Runhuiyi have previously made commitments regarding share restrictions, namely that they will not transfer or entrust others to manage their pre-IPO shares within twelve months from the listing date, nor will the company repurchase these shares. The announcement clarifies that, as of now, these shareholders have not violated their commitments, and this reduction plan strictly complies with their commitments.

Risk Reminder

Xidian Pharmaceutical reminds that the implementation of Hengqin Dingtian and Hengqin Runhuiyi’s reduction plan involves uncertainties. Future implementation will depend on market conditions, the company’s stock price, and other factors. At the same time, this reduction plan will not lead to a change in the company’s control, nor will it significantly impact the company’s equity structure, governance structure, or ongoing operations.

The company states that shareholders will strictly abide by the relevant laws and regulations such as the “Company Law,” “Securities Law,” “Administrative Measures for Shareholders’ Reduction of Listed Companies,” and other normative documents during the reduction period. If regulatory authorities introduce new reduction regulations later, they will be implemented accordingly.

Specific Arrangements for the Reduction Plan

The company will disclose the progress of this reduction plan in a timely manner according to relevant regulations.

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI large model based on third-party databases and does not represent Sina Finance’s views. All information in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. If you have questions, please contact biz@staff.sina.com.cn.

Click to view the original announcement>>

Massive information, precise interpretation, all on Sina Finance APP

Editor: Xiao Lang Express